Lexicon Pharmaceuticals Inc (LXRX) — Cash Flow-to-Debt Ratio
Lexicon Pharmaceuticals Inc (LXRX) has a Cash Flow-to-Debt Ratio of -0.22x as of March 2026, meaning its operating cash flow of $-14.73 Million could theoretically repay 0% of its total liabilities ($65.96 Million) in one year. Check cash flow reinvestment rate of Lexicon Pharmaceuticals Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lexicon Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1999–2025)
Historical debt coverage capacity for Lexicon Pharmaceuticals Inc across 27 annual periods. Also explore how large is Lexicon Pharmaceuticals Inc's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Lexicon Pharmaceuticals Inc (1999–2025)
Year-by-year debt coverage analysis for Lexicon Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Lexicon Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.88x | $-67.85 Million | $77.45 Million | ▲ +25.3% |
| 2024 | -1.17x | $-178.78 Million | $152.47 Million | ▲ +1.3% |
| 2023 | -1.19x | $-161.90 Million | $136.32 Million | ▼ -3.2% |
| 2022 | -1.15x | $-88.85 Million | $77.17 Million | ▲ +69.2% |
| 2021 | -3.73x | $-87.02 Million | $23.31 Million | ▼ -23.8% |
| 2020 | -3.02x | $-142.97 Million | $47.42 Million | ▼ -896.4% |
| 2019 | 0.38x | $113.81 Million | $300.61 Million | ▲ +179.1% |
| 2018 | -0.48x | $-148.61 Million | $310.54 Million | ▲ +0.8% |
| 2017 | -0.48x | $-185.39 Million | $384.44 Million | ▲ +12.6% |
| 2016 | -0.55x | $-175.63 Million | $318.22 Million | ▼ -210.2% |
| 2015 | 0.50x | $184.78 Million | $368.98 Million | ▲ +224.1% |
| 2014 | -0.40x | $-75.62 Million | $187.36 Million | ▲ +53.9% |
| 2013 | -0.88x | $-91.08 Million | $104.00 Million | ▲ +2.6% |
| 2012 | -0.90x | $-94.46 Million | $105.10 Million | ▼ -35.9% |
| 2011 | -0.66x | $-87.94 Million | $132.94 Million | ▲ +3.7% |
| 2010 | -0.69x | $-82.37 Million | $119.86 Million | ▲ +27.2% |
| 2009 | -0.94x | $-89.02 Million | $94.26 Million | ▲ +35.1% |
| 2008 | -1.46x | $-95.60 Million | $65.68 Million | ▼ -62.0% |
| 2007 | -0.90x | $-74.32 Million | $82.72 Million | ▼ -65.4% |
| 2006 | -0.54x | $-56.91 Million | $104.77 Million | ▼ -408.0% |
| 2005 | 0.18x | $23.44 Million | $132.91 Million | ▲ +137.7% |
| 2004 | -0.47x | $-42.26 Million | $90.39 Million | ▼ -614.8% |
| 2003 | -0.07x | $-7.72 Million | $117.98 Million | ▲ +92.8% |
| 2002 | -0.90x | $-28.79 Million | $31.87 Million | ▼ -8.6% |
| 2001 | -0.83x | $-17.99 Million | $21.62 Million | ▼ -624.1% |
| 2000 | -0.11x | $-1.50 Million | $13.06 Million | ▲ +83.1% |
| 1999 | -0.68x | $-9.60 Million | $14.10 Million | — |